Federal Register / Vol. 79, No. 241 / Tuesday, December 16, 2014 / Notices 74731 

listed below. This proposed information 

collection was previously published in 

the Federal Register on August 21, 

2014, page 49523 and allowed 60 days 

for public comment. No public 

comments were received. The purpose 

of this notice is to request an additional 

30 days for public comment and 

reinstatement without change. The 

Center for Scientific Review (CSR), 

National Institutes of Health, may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

information collection that has been 

extended, revised, or implemented on or 

after October 31, 2014, unless it displays 

a currently valid OMB control number. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, OIRA_submission@

omb.eop.gov or by fax to 202–395–6974, 

Attention: NIH Desk Officer. 

DATES: Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project 

contact: Dr. Mary Ann Guadagno, 

Project Clearance Liaison, Center for 

Scientific Review, NIH, Room 3182, 

6701 Rockledge Drive, Bethesda, MD 

20892, or call non-toll-free number (301) 

435–1251 or Email your request, 

including your address to: guadagma@

csr.nih.gov. Formal requests for 

additional plans and instruments must 

be requested in writing. 

Proposed Collection: Generic 

Clearance for Satisfaction Surveys of 

Customers (CSR), 0925–0474 expired 

October 31, 2014-reinstatement without 

change, Center for Scientific Review 

(CSR), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The information collected in 

these surveys will be used by the Center 

for Scientific Review management and 

personnel: (1) To assess the quality of 

the modified operations and processes 

now used by CSR to review grant 

applications; (2) to assess the quality of 

service provided by CSR to our 

customers; (3) to enable identification of 

the most promising biomedical research 

that will have the greatest impact on 

improving public health by using a peer 

review process that is fair unbiased from 

outside influence, timely; and (4) to 

develop new modes of operation based 

on customer need and customer 

feedback about the efficacy of 

implemented modifications. These 

surveys will almost certainly lead to 

quality improvement activities to 

enhance and/or streamline CSR’s 

operations. The major mechanism by 

which CSR will request input is through 

surveys. The major initiatives ongoing at 

the present time include: Evaluation of 

the peer review process, surveys of new 

and early stage investigators, 

satisfaction with study section meetings 

using alternative review platforms, 

quick feedback for peer review, 

satisfaction with new reviewer 

orientation sessions, teleworker space 

needs, improving study section 

alignment to ensure the best reviews, 

and others. Surveys will be collected via 

Internet or in focus groups. Information 

gathered from these surveys will be 

presented to, and used directly by, CSR 

management to enhance the operations, 

processes, organization of, and services 

provided by the Center. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

4323. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hours 

A .................. Adult scientific professionals (via Mail/Telephone/Internet) .. 7925 1 30/60 3963 

B .................. Adult scientific professionals (via focus groups) ................... 240 1 90/60 360 

Dated: December 10, 2014. 

Mary Ann Guadagno, 

Project Clearance Liaison, Center for 

Scientific Review, National Institutes of 

Health. 

[FR Doc. 2014–29460 Filed 12–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

Microscopy System for Distinguishing 

Stimulated Emissions as a Means of 

Increasing Signal 

Description of Technology: The 

invention pertains to a system and 

method for distinguishing stimulated 

emissions as a means of enhancing 

signal strength of fluorescent markers in 

fluorescence microscopy applications. 

The system is arranged such that an 

excitation beam (e.g., laser beam) 

illuminates a sample along some axis 

exciting the fluorescent markers used in 

the sample. A second light beam, a 

stimulation beam, illuminates the 

sample along another axis, possibly the 

same as that of the excitation beam. It 

has been found that if the excited 

fluorescent molecules are illuminated 

with light of a stimulation beam at a 

mstockstill on DSK4VPTVN1PROD with NOTICES

74732 Federal Register / Vol. 79, No. 241 / Tuesday, December 16, 2014 / Notices 

particular wavelength after initial 

excitation, the fluorescent molecules 

will emit light at this wavelength that 

can be separately detected. An excited 

fluorescent molecule may be stimulated 

by light at a wavelength different from 

the initial excitation beam to boost the 

signal. The stimulated emission then 

generated by the fluorescent molecules 

travels along the same access as the 

stimulation beam and, as such, the 

system is configured by a stimulation 

beam block component associated with 

an objective lens that prevents or 

reduces stimulation beam detection but 

allows detection of the stimulated 

emission. Another way the invention 

achieves this is by refocusing both the 

excitation and stimulation beams 

through capture by an excitation 

objective. A filter is then used to filter 

out light focused by the excitation 

objective from the simulated emission 

sent back by the fluorescent molecule. 

Potential Commercial Applications: 

• Fluorescent microscopy 

• Sample detection 

Competitive Advantages: Enhanced 

signal strength in small or dilute 

samples. 

Development Stage: 

• Early-stage 

• Prototype 

Inventors: Andrew York (NIBIB), 

Sanjay Varma (Johns Hopkins 

University). 

Intellectual Property: HHS Reference 

No. E–247–2014/0—U.S. Provisional 

Patent Application 62/072,218 filed 

October 29, 2014. 

Licensing Contact: Michael 

Shmilovich; 301–435–5019; shmilovm@

mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Biological 

Imaging and Bioengineering is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize Fluorescent Microscopy 

resolution enhancement. For 

collaboration opportunities, please 

contact Cecilia Pazman at pazmance@

mail.nih.gov. 

A Novel Virus-Based Expression 

System 

Description of Technology: The 

present invention is related to a 

recombinant viral vector for vaccines. 

Currently available poxvirus vectors 

for humans and other animals exhibit 

suboptimal expression of recombinant 

gene(s) and high expression of vector 

proteins which causes weak 

immunogenicity and high anti-vector 

immune response. 

The present novel virus-based 

expression vectors are non-replicating 

in human and animals, have high 

expression of exogenous genes to 

achieve strong immunogenicity, 

demonstrate low expression of vector 

proteins to minimize anti-vector 

immune responses and minimize 

competition with expression of 

recombinant proteins and are capable of 

stable propagation in a continuous cell 

line. The present virus based expression 

vectors may be suitable for 

manufacturing vaccines for inducing an 

immune response in vaccinated 

individuals. 

Potential Commercial Applications: 

• Vaccine 

• Tool for studying immune 

responses 

Competitive Advantages: 

• Non-replicating in human and 

animals 

• Achieve high expression of 

recombinant genes 

• Low expression of vector genes 

• Stable propagation in a continuous 

cell line 

Development Stage: 

• Early-stage 

• In vitro data available 

• Prototype 

Intellectual Property: HHS Reference 

No. E–181–2014/0—U.S. Provisional 

Application No. 62/055,989 filed 

September 26, 2014. 

Related Technologies: 

• Moss B, et al. Recombinant 

poxviruses having foreign DNA 

expressed under the control of poxvirus 

regulatory sequences. U.S. Patent 

6,998,252 issued February 14, 2006. 

• Moss B, et al. Prokaryotic 

expression in eukaryotic cells. U.S. 

Patent 5,550,035 issued August 27, 

1996. 

Licensing Contact: John Stansberry, 

Ph.D.; 301–435–5236; stansbej@

mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases, Laboratory of Viral 

Diseases, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize A Novel Virus-Based 

Expression System. For collaboration 

opportunities, please contact Chris 

Kornak at chris.kornak@nih.gov. 

Ultra-Sensitive Diagnostic Detects fg/

mL-pg/mL Pathogen/Disease Protein by 

Visual Color Change 

Description of Technology: This 

technology is an ultra-sensitive 

colorimetric assay, based on an enzymecatalyzed gold nanoparticle growth 

process, for detection of diseaseassociated proteins (biomarkers) and 

disease diagnosis. Current detection 

methods, such as ELISA immunoassays, 

measure concentrations above 0.1 ng/

mL in a sample. PCR, although more 

sensitive than ELISA, requires 

expensive and specialized equipment 

and reagents, skilled labor, and complex 

analysis techniques. This assay detects 

fg/mL to pg/mL concentrations, 

allowing detection and diagnosis in the 

earliest stage of disease or infection. A 

simple to read colorless-to-red change of 

gold nanoparticle is read with the naked 

eye, without the need for advanced 

instruments. This assay can be 

performed in a standard ELISA plate. 

Prototype, proof of concept tests using 

this platform have been designed for 

enterovirus 71 (EV71) and prostate 

specific antigen (PSA). The limit of 

detection (LOD) for a PSA prototype 

exceeded the commercial ELISA by 

more than four orders of magnitude. 

This assay may be particularly well 

suited for field use/point-of-care 

detection of infections and early stage 

disease. 

Potential Commercial Applications: 

Infectious pathogen and disease 

diagnostics. 

Competitive Advantages: 

• Orders of magnitude more sensitive 

than most ELISA (detects fg/mL to pg/ 

mL) 

• Plain sight color-based confirmation 

does not require complex equipment 

• Field use/point-of-care detection 

Development Stage: 

• Early-stage 

• In vitro data available 

• Prototype 

Inventors: Dingbin Liu and Xiaoyuan 

Chen (NIBIB) 

Publication: Liu D, et al. Glucose 

oxidase-catalyzed growth of gold 

nanoparticles enables quantitative 

detection of attomolar cancer 

biomarkers. Anal Chem. 2014 Jun 17; 

86(12):5800–6. [PMID 24896231] 

Intellectual Property: 

• HHS Reference No. E–167–2014/

0—U.S. Provisional Application No. 61/ 

994,622 filed May 16, 2014 

• HHS Reference No. E–167–2014/

1—U.S. Provisional Application No. 62/ 

052,866 filed September 19, 2014 

Licensing Contact: Edward (Tedd) 

Fenn; 424–297–0336; tedd.fenn@

nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Biomedical 

Imaging and Bioengineering is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Cecilia Pazman, Ph.D. at 

pazmance@mail.nih.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 241 / Tuesday, December 16, 2014 / Notices 74733 

Cannabinoid Receptor Meditating 

Compounds for Metabolic Disease 

Description of Technology: There is 

evidence that the metabolic effects of 

endocannabinoids are mediated by CB1 

receptors in peripheral tissues. While 

prior attempts at generating CB1 

receptor blockers have had serious 

neuropsychiatric side effects, inventors 

at NIH have discovered compounds that 

block CB1 receptors with reduced brain 

penetrance. In addition, some of these 

compounds also have a direct inhibitory 

effect on inducible nitric oxide synthase 

(iNOS), whereas another group of the 

compounds directly activates AMP 

kinas. These dual-target compounds 

may be useful for treating metabolic 

disease and related conditions such as 

obesity and diabetes and their 

complications, including liver or kidney 

fibrosis, without the dangerous the side 

effects. 

Potential Commercial Applications: 

Treatment of metabolic disease and 

related conditions such as diabetes, 

obesity and fibrotic disease. 

Competitive Advantages: Cannabinoid 

receptor blockers with reduced brain 

penetrance relative to older drugs of this 

class, also having secondary target for 

improved therapeutic efficacy. 

Development Stage: Early-stage. 

Inventors: George Kunos (NIAAA), 

Malliga R. Iyer (NIAAA), Resat Cinar 

(NIAAA), Kenner C. Rice (NIDA). 

Intellectual Property: HHS Reference 

No. E–140–2014/0—U.S. Provisional 

Application No. 61/991,333 filed May 9, 

2014. 

Related Technologies: 

• HHS Reference No. E–211–2006/

0—U.S. Patent No. 8,293,724 issued 

October 23, 2012 

• HHS Reference No. E–282–2012/

0—PCT Application No. PCT/

US2013069686 filed December 11, 2013 

• HHS Reference No. E–103–2013/

0—PCT Application No. PCT/US2014/

043924 filed June 24, 2014 

Licensing Contact: Jaime M. Greene; 

301–435–5559; greenejaime@

mail.nih.gov. 

Octopod (8-Pointed Star-Shape) Iron 

Oxide Nanoparticles Enhance MRI T2

Contrast 

Description of Technology: The 

octopod-shaped iron oxide 

nanoparticles of this technology 

significantly enhance contrast in MRI 

imaging compared to spherical 

superparamagnetic iron oxide 

nanoparticle T2 contrast agents. These 

octopod iron oxide nanoparticles show 

a transverse relaxivity that is over five 

times greater than comparable spherical 

agents. Because the unique octopod 

shape creates a greater effective radius 

than spherical agents, but maintains 

similar magnetization properties, the 

relaxation rate is improved. The 

improved relaxation rate greatly 

enhances the contrast of images. These 

octopod agents appear to be biocompatible and may be suitable for 

intravenous delivery. The synthesis of 

these agents is also easily reproducible 

and scaled. The superior contrast greatly 

improves diagnostic sensitivities, 

compared to current FDA approved 

spherical contrast agents. These 

octopod-shaped iron oxide nanoparticle 

T2 contrast agents may have a number 

of medical imaging uses, such as tumor 

detection, atherosclerosis imaging and 

delivery of therapeutic treatments. 

Potential Commercial Applications: 

Medical imaging, such as tumor 

detection, atherosclerosis imaging and 

delivery of therapeutic treatments. 

Competitive Advantages: 

• Enhanced T2 contrast 

• Reproducible and scalable synthesis 

• Improved imaging and diagnostic 

capability 

Development Stage: In vivo data 

available (animal). 

Inventors: Xiaoyuan Chen (NIBIB), 

Jinhao Gao (Xiamen University, China), 

Zhenghuan Zhao (Xiamen University, 

China). 

Publication: Zhao Z, et al. Octapod 

iron oxide nanoparticles as highperformance T2 contrast agents for 

magnetic resonance imaging. Nat 

Commun. 2013; 4:2266. [PMID 

23903002]. 

Intellectual Property: HHS Reference 

No. E–314–2013/0—PCT Application 

No. PCT/CN2013/076645 filed June 3, 

2013. 

Licensing Contact: Edward (Tedd) 

Fenn; 424–297–0336; tedd.fenn@

nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Biomedical 

Imaging and Bioengineering is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize this technology. For 

collaboration opportunities, please 

contact Cecilia Pazman, Ph.D. at 

pazmance@mail.nih.gov. 

Dated: December 9, 2014. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2014–29319 Filed 12–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Translational. 

Date: January 23, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Monaco, 700 F Street NW., 

Washington, DC 20004. 

Contact Person: Joel A. Saydoff, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3205, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

9223, joel.saydoff@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: December 9, 2014. 

Carolyn Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–29322 Filed 12–15–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

mstockstill on DSK4VPTVN1PROD with NOTICES